Publications by authors named "S Ganesananthan"
Background: Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many patients. The reason for this was unclear.
Objectives: This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, noninvasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI.
Background: In stable coronary artery disease, 30% to 60% of patients remain symptomatic despite successful revascularization. Perhaps not all symptoms reported by a patient with myocardial ischemia are, in fact, angina.
Objectives: This study sought to determine whether independent symptom verification using a placebo-controlled ischemic stimulus could distinguish which patients achieve greatest symptom relief from percutaneous coronary intervention (PCI).
Importance: Unlike medications, procedural interventions are rarely trialed against placebo prior to becoming accepted in clinical practice. When placebo-controlled trials are eventually conducted, procedural interventions may be less effective than previously believed.
Objective: To investigate the importance of including a placebo arm in trials of surgical and interventional procedures by comparing effect sizes from trials of the same procedure that do and do not include a placebo arm.
Article Synopsis
- A study was done to see if a procedure called PCI helps people with stable angina (chest pain) feel better than a fake (placebo) procedure.
- 301 patients were divided into two groups: one had the PCI and the other had the fake procedure for 12 weeks.
- The results showed that those who had PCI had better scores for their angina symptoms, meaning they felt less pain compared to the placebo group.
Article Synopsis
- - ATTR-CM is a form of heart failure linked to a specific TTR gene mutation (p.(V142I)) prevalent in 3-4% of individuals of African descent, potentially affecting 1.6 million people in the U.S.
- - A study analyzed 413 patients with this mutation, finding that they had significant heart functional impairment and lower 5-year survival rates compared to patients with wild-type ATTR-CM, emphasizing the seriousness of the condition.
- - The aggressive nature of p.(V142I)-ATTRv-CM was highlighted by findings of myocyte loss and widespread infiltration in the heart muscle, indicating a high risk for biventricular failure and poor patient outcomes.